Cronos (CRON) revenue breakdown
By segment, Rest of World is the largest at 94% of fiscal 2022 revenue, growing 62% a year over 3 years.
By product, Cannabis flower is the largest at 74% of fiscal 2025 revenue; Cannabis extracts grew fastest, 45% a year over 7 years.
Revenue by segment
Fiscal years, as Cronos reports them in its 10-K filings; fiscal 2022 total $92M.
| Segments | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|
| Rest of World | $20M | $37M | $65M | $87M | 94% |
| United States | $3M | $9M | $10M | $5M | 6% |
Revenue by product
Fiscal years, as Cronos reports them in its 10-K filings; fiscal 2025 total $147M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Cannabis flower | $9M | $15M | $28M | $55M | $64M | $62M | $88M | $108M | 74% |
| Cannabis extracts | $3M | $9M | $18M | $9M | $23M | $25M | $29M | $38M | 26% |
| Other | $179,000 | $28,000 | $533,000 | $560,000 | $634,000 | $602,000 | $535,000 | $411,000 | 0% |
Revenue by region
Fiscal years, as Cronos reports them in its 10-K filings; fiscal 2025 total $147M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Canada | — | — | $20M | $35M | $50M | $56M | $65M | $82M | $90M | 62% |
| Israel | — | — | — | $3M | $13M | $31M | $21M | $28M | $42M | 29% |
| Other countries | — | — | — | — | $891,000 | — | $1M | $7M | $14M | 10% |
| Canadian | $3M | $16M | — | — | — | — | — | — | — | — |
| United States | — | — | $3M | $9M | — | — | — | — | — | — |
| International | $599,000 | $1M | — | — | — | — | — | — | — | — |
| Other countries | — | — | $184,000 | $147,000 | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CRON.
Open CRON in InvestinglyQuestions
Where does Cronos make its money?
In fiscal 2022, by segment: Rest of World $87M, United States $5M.
From Cronos's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.